Last ¥1,515 JPY
Change Today +10.00 / 0.66%
Volume 1.1M
As of 2:00 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

mitsubishi tanabe pharma (4508) Snapshot

Open
¥1,505
Previous Close
¥1,505
Day High
¥1,535
Day Low
¥1,503
52 Week High
01/21/14 - ¥1,552
52 Week Low
08/8/13 - ¥1,311
Market Cap
850.5B
Average Volume 10 Days
608.9K
EPS TTM
¥79.45
Shares Outstanding
561.4M
EX-Date
09/26/14
P/E TM
19.1x
Dividend
¥40.00
Dividend Yield
2.64%
Current Stock Chart for MITSUBISHI TANABE PHARMA (4508)

Related News

No related news articles were found.

mitsubishi tanabe pharma (4508) Related Businessweek News

No Related Businessweek News Found

mitsubishi tanabe pharma (4508) Details

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan and internationally. The company offers autoimmune drugs, including Remicade agent for rheumatoid arthritis and Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis; and Simponi agent for rheumatoid arthritis. It also provides drugs for diabetes and kidney diseases, such as Kremezin agent for chronic renal failure; and Tanatril agent for hypertension and diabetic nephropathy with diabetes mellitus, etc. In addition, the company offers drugs for central nervous system diseases comprising Radicut, a cerebral neuroprotectant; Ceredist agent for spinocerebellar degeneration; Depas, an anti-anxiety agent; and Lexapro, an anti-depressant agent. Further, it provides Maintate agent for hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Talion agent for allergic disorders; Urso agent for the improvement of hepatic, biliary, and digestive function; Venoglobulin IH, an intravenous human immunoglobulin; Anplag, an anti-platelet agent; and Herbesser, an agent for angina pectoris and hypertension. Additionally, the company offers vaccines, such as TETRABIK, a combined vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; and influenza. It also provides over-the-counter products, including herbal and digestive medicines, as well as oral solutions for tonic and nutritional supplement; and products for the treatment of skin conditions, allergic rhinitis, and recurrent vaginal candidiasis. The company also offers pharmaceutical information and real estate management services; sells generic pharmaceuticals, chemicals, etc.; invests in bio-ventures; and is involved in distribution and warehouse operations. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

9,065 Employees
Last Reported Date: 06/20/14
Founded in 1678

mitsubishi tanabe pharma (4508) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mitsubishi tanabe pharma (4508) Key Developments

Mitsubishi Tanabe Announces Earnings Results for the First Quarter of 2014

Mitsubishi Tanabe announced earnings results for the first quarter of 2014. For the quarter, the company reported that its sales fell by 9.0% year on year to stand at JPY 94.56 billion. Over the same period, the company's operating income plummeted by 15.7% to JPY 13.68 billion, while its net income was down by 7.9% to JPY 9.59 million.

Mitsubishi Tanabe Pharma Corporation Projects Dividend for the Second Quarter of Fiscal 2015

Mitsubishi Tanabe Pharma Corporation announced that it projected dividend of ¥20.00 per share for the second quarter of fiscal 2015.

Mitsubishi Tanabe Pharma Corporation to Report Q1, 2015 Results on Jul 29, 2014

Mitsubishi Tanabe Pharma Corporation announced that they will report Q1, 2015 results on Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4508:JP ¥1,515.00 JPY +10.00

4508 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4508.
View Industry Companies
 

Industry Analysis

4508

Industry Average

Valuation 4508 Industry Range
Price/Earnings 18.7x
Price/Sales 2.1x
Price/Book 1.1x
Price/Cash Flow 14.8x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MITSUBISHI TANABE PHARMA, please visit www.mt-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.